Generic Name and Formulations:
Cefadroxil 500mg; caps.
Various generic manufacturers
Indications for Cefadroxil:
Susceptible urinary tract, skin and skin structure infections, pharyngitis/tonsillitis, impetigo.
Uncomplicated UTI: 1–2g once daily or in 2 divided doses. Complicated UTI: 2g/day in 2 divided doses. Skin and skin structure infections: 1g once daily or in 2 divided doses. Pharyngitis/tonsillitis: 1g once daily or in 2 divided doses for 10 days. Renal dysfunction (CrCl <50mL/min): 1g loading dose, then 500mg at increased dosing intervals (see literature). Continue for 3 days after symptoms improve.
UTI, skin and skin structure infections: 30mg/kg/day in 2 divided doses every 12 hours. Pharyngitis/tonsillitis, impetigo: 30mg/kg once daily or in 2 divided doses for 10 days. Renal dysfunction: reduce dose (see literature). Continue for 3 days after symptoms improve.
Penicillin or other allergy. Discontinue if colitis occurs and treat. Impaired renal function (CrCl <50mL/min). GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) Clinitest or Coomb's test.
GI upset, anaphylaxis, rash; blood dyscrasias (rare).
Formerly known under the brand names Duricef, Ultracef.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC